Medicare AdvantageCoverageMedium impact
MA08.073s, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.073s regarding intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors has been updated effective July 1, 2025. This policy affects coverage and billing for eye injections used to treat conditions like macular degeneration and diabetic retinopathy.
Action Required
By July 1, 2025: Ophthalmology and retina specialists must review updated Medicare Advantage policy MA08.073s for intravitreal VEGF injections. Access the full policy details at the source URL to understand any changes to coverage criteria, prior authorization requirements, or documentation standards for VEGF antagonist injections.